Neurocrine Biosciences, Inc. - Common Stock (NQ:NBIX)

143.18 +2.47 (+1.76%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Neurocrine Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

What Analysts Are Saying About Neurocrine Biosciences Stock ↗

December 20, 2024

Via Benzinga

Neurocrine's Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential ↗

December 16, 2024

Neurocrine's Crenessity receives FDA approval as a groundbreaking adjunctive treatment for classic CAH, offering a novel approach to hormone regulation.

Via Benzinga

Neurocrine Wins FDA Approval For Genetic Disorder Drug ↗

December 13, 2024

The company can launch within a week, says Chief Executive Kyle Gano.

Via Investor's Business Daily

Screening For Black Friday Bargains In The Stock Market ↗

December 03, 2024

Via Benzinga

For those who appreciate growth without the sticker shock, NASDAQ:NBIX is worth considering. ↗

December 03, 2024

NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) stands out as a growth opportunity that won't break the bank.

Via Chartmill

NASDAQ:NBIX qualifies as a high growth stock and is consolidating. ↗

November 28, 2024

Is NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) on the Verge of a Major Breakout as a Strong Growth Stock?

Via Chartmill

NASDAQ:NBIX stands out as a growth opportunity that won't break the bank. ↗

November 12, 2024

Looking for growth without the hefty price tag? Consider NASDAQ:NBIX.

Via Chartmill

NASDAQ:NBIX—A High-Growth Stock Gearing Up for Its Next Upward Move. ↗

September 19, 2024

Why NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Is a Standout High-Growth Stock in a Consolidation Phase.

Via Chartmill

Decoding 19 Analyst Evaluations For Neurocrine Biosciences ↗

September 09, 2024

Via Benzinga

NASDAQ:NBIX stands out as a stock that provides good value for the fundamentals it showcases. ↗

November 19, 2024

NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) is an undervalued gem with solid fundamentals.

Via Chartmill

AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio ↗

November 12, 2024

AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience strategy and boosting competition for Cobenfy.

Via Benzinga

In-Depth Examination Of 20 Analyst Recommendations For Neurocrine Biosciences ↗

October 29, 2024

Via Benzinga

NASDAQ:NBIX stands out as a growth opportunity that won't break the bank. ↗

October 22, 2024

Investors should take note of NASDAQ:NBIX, a growth stock that remains attractively priced.

Via Chartmill

NASDAQ:NBIX appears to be flying under the radar despite its strong fundamentals. ↗

October 21, 2024

NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.

Via Chartmill

Why NASDAQ:NBIX Is a Promising High-Growth Stock in the Midst of Consolidation. ↗

October 11, 2024

NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX)—Positioned as a High-Growth Stock, Ready for a Potential Breakout.

Via Chartmill

NASDAQ:NBIX, a growth stock which is not overvalued. ↗

September 09, 2024

Investors should take note of NASDAQ:NBIX, a growth stock that remains attractively priced.

Via Chartmill

Critical Insights From Neurocrine Biosciences Analyst Ratings: What You Need To Know ↗

October 04, 2024

Via Benzinga

"Rule Breaker Investing" Market Cap Game Show: Throwdowns & Long-Term Wins ↗

September 30, 2024

Motley Fool analysts Matt Argersinger and Yasser El-Shimy face off.

Via The Motley Fool

Despite its growth, NASDAQ:NBIX remains within the realm of affordability. ↗

September 30, 2024

In the world of growth stocks, NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) shines as a value proposition.

Via Chartmill

For those who appreciate value investing, NASDAQ:NBIX is a compelling option with its solid fundamentals. ↗

September 26, 2024

NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) is probably undervalued for the fundamentals it is displaying.

Via Chartmill

Neurocrine Shifts Focus To New Schizophrenia Treatment After Luvadaxistat Trial Misses Endpoint ↗

September 13, 2024

Neurocrine Biosciences announced that its ERUDITE Phase 2 trial for luvadaxistat failed to meet its primary endpoint in treating cognitive impairment in schizophrenia. The company will halt development...

Via Benzinga

Intel, Moderna And Dollar General Were Among Top 10 Large Cap Losers In August: Are The Others In Your Portfolio? ↗

September 08, 2024

10 worst performing large-cap stocks in August: Super Micro, Dollar General, Snap, PDD Holdings, Intel, Tencent Music, Gold Fields, Charles River, Moderna, Neurocrine Biosciences.

Via Benzinga

Don't overlook NASDAQ:NBIX—it's a hidden gem with strong fundamentals and an attractive price tag. ↗

September 05, 2024

NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) stands out as a stock that provides good value for the fundamentals it showcases.

Via Chartmill

Dollar General, Temu Parent PDD And Super Micro Computer Are Among Top 10 Large Cap Losers Last Week (Aug 25-Aug 31): Are The Others In Your Portfolio? ↗

September 02, 2024

10 worst performing large-cap stocks in the last week. Dollar General, Super Micro Computer, Okta, Pure Storage, Neurocrine Biosciences among them.

Via Benzinga

Stock Market Rally Mixed; Dow Jones Hits High While Nvidia Tumbles On Earnings: Weekly Review ↗

August 30, 2024

The Dow Jones hit a new high while Nvidia led a Nasdaq retreat.

Via Investor's Business Daily

Topics Stocks

Why Neurocrine Biosciences Stock Was Tumbling This Week ↗

August 30, 2024

The company promises to advance a top investigational drug to late-stage testing, but investors might not think that's a fine idea.

Via The Motley Fool

Neurocrine Biosciences' Lower Dose Data Puts Its Schizophrenia Candidate In The Game, Analyst Upgrades Stock ↗

August 29, 2024

Neurocrine Biosciences reports positive Phase 2 trial results for NBI-1117568 in adults with schizophrenia, showing significant reduction in PANSS scores with a 20 mg dose. Piper Sandler upgrades the...

Via Benzinga

NVIDIA To Rally Over 31%? Here Are 10 Top Analyst Forecasts For Thursday ↗

August 29, 2024

Via Benzinga

Nasdaq Down Over 1%; Foot Locker Shares Tumble After Q2 Results ↗

August 28, 2024

Via Benzinga

As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors ↗

August 28, 2024

Neurocrine Biosciences reports Phase 2 trial results for NBI-1117568 showing significant improvement in schizophrenia symptoms, with an 18.2-point reduction in PANSS scores at a 20 mg dose.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.